ArticleVaccines2022
Seroprevalence of Pertussis in Adults at Childbearing Age Pre- and Post- COVID-19 in Beijing, China.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Seroprevalence of IgG antibodies against pertussis toxin in the Chinese population: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Antibody waning and Bordetella pertussis resurgence after the COVID-19 pandemic in the Netherlands.Nature communications · 2026Article
- Pertussis epidemiology and seroprevalence in Wujin District, Changzhou, China, 2024.BMC infectious diseases · 2026Article
- Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review.Infectious diseases and therapy · 2026Review
- Analysis of pertussis surveillance data (2022-2023) in a district of Beijing.BMC infectious diseases · 2025Article
- The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic.Human vaccines & immunotherapeutics · 2024Article
- Seroprevalence of tetanus and pertussis antibodies among health care workers in Wuhu, China.Human vaccines & immunotherapeutics · 2024Article
- Seroepidemiology of pertussis immunity in five provinces of China: A population-based, cross-sectional study.Human vaccines & immunotherapeutics · 2024Article
- Impact of COVID-19 Nonpharmaceutical Interventions onOpen forum infectious diseases · 2024Review
- Article
- Genome-based prediction of cross-protective, HLA-DR-presented epitopes as putative vaccine antigens for multipleMicrobiology spectrum · 2024Article
- Post-COVID-19 pandemic changes in pertussis incidence among patients with acute respiratory tract infections in Zhejiang, China.Frontiers in microbiology · 2024Article
- Article
- The Decay of Pertussis Antibodies in Children Aged 0-14 Years in Jiangsu Province, China.Vaccines · 2023Article
- Article
- Pertussis Prevalence in Adult Population in Greece: A Seroprevalence Nationwide Study.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of reported pertussis cases has significantly decreased during the coronavirus disease 2019 (COVID-19) pandemic under the influence of strict public health measures in many countries including China. This study evaluated the prevalence of serum anti-pertussis toxin (anti-PT) IgG antibodies in adults at childbearing age pre- and post- COVID-19 in Beijing, China. Altogether, 2021 serum samples collected from individuals aged 20 to 39 years who attended an annual health examination at the Sixth Medical Center of PLA General Hospital, Beijing, in 2018~2020 were measured by ELISA. The median concentration of anti-PT IgG antibodies among participants in 2020 (2.96 IU/mL) was significantly lower than that in 2018 (3.27 IU/mL) (p = 0.011) and in 2019 (3.24 IU/mL) (p = 0.014). The percentage of participants with anti-PT IgG antibodies higher than 40 IU/mL (indicating a pertussis infection within the past few years) was 1.79% (9/503) in 2018, 2.04% (15/735) in 2019 and 1.66% (13/783) in 2020, respectively. The corresponding numbers of the non-detectable (<5 IU/mL) rate of anti-PT IgG antibodies were 66.60%, 65.99% and 70.24%. Our results showed that there was a significant difference between true and reported incidence rates even during the COVID-19 pandemic. The proportion of adults at childbearing age without pertussis-specific antibodies is high, suggesting that booster vaccinations in adults should be considered in this country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.